Research & Development
-
Podcast
Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye
The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.
By Taren Grom • Feb. 8, 2023 -
Profile
The unique playbook of Biohaven’s CEO
Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?
By Meagan Parrish • Feb. 8, 2023 -
Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer
A growing number of fungal infections has caused a stir in the research community, and new vaccines could be the answer down the road.
By Michael Gibney • Feb. 7, 2023 -
Q&A // First 90 Days
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
By Kelly Bilodeau • Feb. 6, 2023 -
Q&A // Biotech Spotlight
Astria Therapeutics’ edge in an ultra-rare disease
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
By Taren Grom • Feb. 1, 2023 -
Podcast
Woman of the Week: Bayer’s Dr. Yesmean Wahdan
The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.
By Taren Grom • Feb. 1, 2023 -
Weight loss drugs: the promise and pitfalls
GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.
By Kelly Bilodeau • Jan. 30, 2023 -
Profile
A biotech CEO’s favorite ‘F’ word
At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.
By Taren Grom • Jan. 26, 2023 -
Q&A
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
By Meagan Parrish • Jan. 26, 2023 -
Report reveals murky picture of clinical trial diversity gains
Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.
By Alexandra Pecci • Jan. 24, 2023 -
Q&A
Already on a roll in oncology, Astellas hunts for big wins in other areas
With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point.
By Karissa Waddick • Jan. 23, 2023 -
Q&A
A Moderna tie-up ushers in new era for CytomX
The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.
By Michael Gibney • Jan. 18, 2023 -
Podcast
Woman of the Week: Genetika+’s Talia Cohen Solal
The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.
By Taren Grom • Jan. 18, 2023 -
Profile
Pro sports’ COVID protocols led to real-world data impacts for pharma
After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.
By Karissa Waddick • Jan. 16, 2023 -
Space — the next frontier in drug development
Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.
By Kelly Bilodeau • Jan. 12, 2023 -
Podcast
Woman of the Week: Form Bio’s Claire Aldridge
The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
By Taren Grom • Jan. 11, 2023 -
Q&A // Biotech Spotlight
Galecto has identified a master switch to reduce fibroid formation
With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.
By Taren Grom • Jan. 11, 2023 -
Biotech Spotlight
Chinook Therapeutics nears the finish line in kidney disease
A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.
By Michael Gibney • Jan. 10, 2023 -
The kindred nature of martial arts and drug development
How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.
By Alexandra Pecci • Jan. 9, 2023 -
Q&A // Biotech Spotlight
Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
By Taren Grom • Jan. 9, 2023 -
Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023
As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.
By Michael Gibney • Jan. 5, 2023 -
Nonprofits are bridging R&D’s valley of death
How charitable firms such as Advancium are helping to right the market wrongs of drug development.
By Kelly Bilodeau • Jan. 4, 2023 -
Podcast
Woman of the Week: Cambrian BioPharma’s Juliette Han
The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.
By Taren Grom • Jan. 4, 2023 -
Profile
Forks in the road lead one medical expert to a ‘game changing’ liver treatment
Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.
By Alexandra Pecci • Jan. 3, 2023 -
Opinion
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023